Germany
· Delayed Price · Currency is EUR Xeris Biopharma Holdings Company Description
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome.
It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism.
The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
| Country | United States |
| Founded | 2005 |
| Industry | Pharmaceutical Preparations |
| Employees | 394 |
| CEO | John Shannon |
Contact Details
Address: 1375 West Fulton Street Chicago, Delaware 60607 United States | |
| Phone | 844 445 5704 |
| Website | xerispharma.com |
Stock Details
| Ticker Symbol | 2B30 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John Shannon | Chief Executive Officer |
| Steven Pieper | Chief Financial Officer |
| Kevin McCulloch | Chief Operating Officer |
| Allison Wey | Head of Investor Relations |